Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes

Kevin Tyan; Ji Eun Bae; Jochen H. Lorch; Danielle N. Margalit; Roy B. Tishler; Mai Anh Huynh; Vickie Y. Jo; Robert I. Haddad; Nicole G. Chau; Glenn J. Hanna; Jonathan D. Schoenfeld

doi:10.1002/hed.26964

Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes

Kevin Tyan, Ji Eun Bae, Jochen H. Lorch, Danielle N. Margalit, Roy B. Tishler, Mai Anh Huynh, Vickie Y. Jo, Robert I. Haddad, Nicole G. Chau, Glenn J. Hanna, Jonathan D. Schoenfeld^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Background: There is limited information on the management and outcomes of oligometastases (OM) in adenoid cystic carcinoma (ACC). Methods: Retrospective study of 42 patients with metastatic ACC of the head and neck. Imaging studies were analyzed to identify patients with OM (1–5 lesions) at any point during follow-up. Results: There was radiographic evidence of OM in 33/42 (79%) patients. Eighteen patients had OM when treated for metastases, with median overall survival (OS) of 36.0 versus 9.2 years for patients with polymetastases (6+ lesions, HR 0.38, 95%CI 0.14–0.89). Earlier locally ablative treatment, but not systemic treatment, of patients with OM predicted improved survival 3 years after metastasis (HR 0.15, 95%CI 0.02–0.63) and postponed systemic treatment by 80 more months (HR 0.22, 95%CI 0.07–0.71). Conclusions: There is a considerable population of ACC patients with detectable oligometastases, and early locally ablative treatment of oligometastases may be associated with improved outcomes.

Original language	English (US)
Pages (from-to)	722-734
Number of pages	13
Journal	Head and Neck
Volume	44
Issue number	3
DOIs	https://doi.org/10.1002/hed.26964
State	Published - Mar 2022

Funding

J.H.L. receives research support from Novartis, Bayer, BMS and Takeda; consulting and honoraria: Bayer, Genentech. R.B.T. is on the data safety monitoring board for PSI/Oragenics, advisory board for Regeneron. M.A.H. receives research support from the Dana Farber Early Career Innovation Fund, the Harvard Joint Center for Radiation Therapy Research Grant, and ViewRay. R.I.H. receives research support from Pfizer, Genentech, Merck, BMS, Kura, AZ, and GSK; consulting for Merck, GSK, BMS, Genentech, Bayer, Pfizer, Immunomic, Nanobiotix, ISA, Glenmark, AZ. N.G.C. receives research support from GSK, Merck, and Pfizer; honoraria: Eisai, Roche, BMS. G.J.H. is funded by the V Foundation. He receives institutional research support from Kartos and Elevar. Consulting and honoraria from Kura and Prelude. J.D.S. receives research support from ACCRF, Merck, BMS, and Regeneron; consulting and advisory board: Debiopharm, BMS, ACI Clinical, Tilos, LEK, Catenion, Nanobiotix, SAB Immunitas and AZ. The remaining authors have no conflict of interest.

Keywords

adenoid cystic carcinoma
head and neck neoplasms
locally ablative therapy
oligometastatic
survival
systemic therapy
treatment interval
tumor burden

ASJC Scopus subject areas

Otorhinolaryngology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/hed.26964

Cite this

@article{6486dac412e540e3bf2bbdfceabd7ca9,

title = "Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes",

abstract = "Background: There is limited information on the management and outcomes of oligometastases (OM) in adenoid cystic carcinoma (ACC). Methods: Retrospective study of 42 patients with metastatic ACC of the head and neck. Imaging studies were analyzed to identify patients with OM (1–5 lesions) at any point during follow-up. Results: There was radiographic evidence of OM in 33/42 (79%) patients. Eighteen patients had OM when treated for metastases, with median overall survival (OS) of 36.0 versus 9.2 years for patients with polymetastases (6+ lesions, HR 0.38, 95%CI 0.14–0.89). Earlier locally ablative treatment, but not systemic treatment, of patients with OM predicted improved survival 3 years after metastasis (HR 0.15, 95%CI 0.02–0.63) and postponed systemic treatment by 80 more months (HR 0.22, 95%CI 0.07–0.71). Conclusions: There is a considerable population of ACC patients with detectable oligometastases, and early locally ablative treatment of oligometastases may be associated with improved outcomes.",

keywords = "adenoid cystic carcinoma, head and neck neoplasms, locally ablative therapy, oligometastatic, survival, systemic therapy, treatment interval, tumor burden",

author = "Kevin Tyan and Bae, {Ji Eun} and Lorch, {Jochen H.} and Margalit, {Danielle N.} and Tishler, {Roy B.} and Huynh, {Mai Anh} and Jo, {Vickie Y.} and Haddad, {Robert I.} and Chau, {Nicole G.} and Hanna, {Glenn J.} and Schoenfeld, {Jonathan D.}",

note = "Funding Information: J.H.L. receives research support from Novartis, Bayer, BMS and Takeda; consulting and honoraria: Bayer, Genentech. R.B.T. is on the data safety monitoring board for PSI/Oragenics, advisory board for Regeneron. M.A.H. receives research support from the Dana Farber Early Career Innovation Fund, the Harvard Joint Center for Radiation Therapy Research Grant, and ViewRay. R.I.H. receives research support from Pfizer, Genentech, Merck, BMS, Kura, AZ, and GSK; consulting for Merck, GSK, BMS, Genentech, Bayer, Pfizer, Immunomic, Nanobiotix, ISA, Glenmark, AZ. N.G.C. receives research support from GSK, Merck, and Pfizer; honoraria: Eisai, Roche, BMS. G.J.H. is funded by the V Foundation. He receives institutional research support from Kartos and Elevar. Consulting and honoraria from Kura and Prelude. J.D.S. receives research support from ACCRF, Merck, BMS, and Regeneron; consulting and advisory board: Debiopharm, BMS, ACI Clinical, Tilos, LEK, Catenion, Nanobiotix, SAB Immunitas and AZ. The remaining authors have no conflict of interest. Publisher Copyright: {\textcopyright} 2021 Wiley Periodicals LLC.",

year = "2022",

month = mar,

doi = "10.1002/hed.26964",

language = "English (US)",

volume = "44",

pages = "722--734",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "John Wiley & Sons Inc.",

number = "3",

}

TY - JOUR

T1 - Oligometastatic adenoid cystic carcinoma

T2 - Correlating tumor burden and time to treatment with outcomes

AU - Tyan, Kevin

AU - Bae, Ji Eun

AU - Lorch, Jochen H.

AU - Margalit, Danielle N.

AU - Tishler, Roy B.

AU - Huynh, Mai Anh

AU - Jo, Vickie Y.

AU - Haddad, Robert I.

AU - Chau, Nicole G.

AU - Hanna, Glenn J.

AU - Schoenfeld, Jonathan D.

N1 - Funding Information: J.H.L. receives research support from Novartis, Bayer, BMS and Takeda; consulting and honoraria: Bayer, Genentech. R.B.T. is on the data safety monitoring board for PSI/Oragenics, advisory board for Regeneron. M.A.H. receives research support from the Dana Farber Early Career Innovation Fund, the Harvard Joint Center for Radiation Therapy Research Grant, and ViewRay. R.I.H. receives research support from Pfizer, Genentech, Merck, BMS, Kura, AZ, and GSK; consulting for Merck, GSK, BMS, Genentech, Bayer, Pfizer, Immunomic, Nanobiotix, ISA, Glenmark, AZ. N.G.C. receives research support from GSK, Merck, and Pfizer; honoraria: Eisai, Roche, BMS. G.J.H. is funded by the V Foundation. He receives institutional research support from Kartos and Elevar. Consulting and honoraria from Kura and Prelude. J.D.S. receives research support from ACCRF, Merck, BMS, and Regeneron; consulting and advisory board: Debiopharm, BMS, ACI Clinical, Tilos, LEK, Catenion, Nanobiotix, SAB Immunitas and AZ. The remaining authors have no conflict of interest. Publisher Copyright: © 2021 Wiley Periodicals LLC.

PY - 2022/3

Y1 - 2022/3

N2 - Background: There is limited information on the management and outcomes of oligometastases (OM) in adenoid cystic carcinoma (ACC). Methods: Retrospective study of 42 patients with metastatic ACC of the head and neck. Imaging studies were analyzed to identify patients with OM (1–5 lesions) at any point during follow-up. Results: There was radiographic evidence of OM in 33/42 (79%) patients. Eighteen patients had OM when treated for metastases, with median overall survival (OS) of 36.0 versus 9.2 years for patients with polymetastases (6+ lesions, HR 0.38, 95%CI 0.14–0.89). Earlier locally ablative treatment, but not systemic treatment, of patients with OM predicted improved survival 3 years after metastasis (HR 0.15, 95%CI 0.02–0.63) and postponed systemic treatment by 80 more months (HR 0.22, 95%CI 0.07–0.71). Conclusions: There is a considerable population of ACC patients with detectable oligometastases, and early locally ablative treatment of oligometastases may be associated with improved outcomes.

AB - Background: There is limited information on the management and outcomes of oligometastases (OM) in adenoid cystic carcinoma (ACC). Methods: Retrospective study of 42 patients with metastatic ACC of the head and neck. Imaging studies were analyzed to identify patients with OM (1–5 lesions) at any point during follow-up. Results: There was radiographic evidence of OM in 33/42 (79%) patients. Eighteen patients had OM when treated for metastases, with median overall survival (OS) of 36.0 versus 9.2 years for patients with polymetastases (6+ lesions, HR 0.38, 95%CI 0.14–0.89). Earlier locally ablative treatment, but not systemic treatment, of patients with OM predicted improved survival 3 years after metastasis (HR 0.15, 95%CI 0.02–0.63) and postponed systemic treatment by 80 more months (HR 0.22, 95%CI 0.07–0.71). Conclusions: There is a considerable population of ACC patients with detectable oligometastases, and early locally ablative treatment of oligometastases may be associated with improved outcomes.

KW - adenoid cystic carcinoma

KW - head and neck neoplasms

KW - locally ablative therapy

KW - oligometastatic

KW - survival

KW - systemic therapy

KW - treatment interval

KW - tumor burden

UR - http://www.scopus.com/inward/record.url?scp=85121465297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121465297&partnerID=8YFLogxK

U2 - 10.1002/hed.26964

DO - 10.1002/hed.26964

M3 - Article

C2 - 34927307

AN - SCOPUS:85121465297

SN - 1043-3074

VL - 44

SP - 722

EP - 734

JO - Head and Neck

JF - Head and Neck

IS - 3

ER -

Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this